Leukemia Research
Volume 34, Issue 1 , Pages 24-31 , January 2010

In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia

  • Pascale Schneider

      Affiliations

    • Pediatric Hematology, Oncology and IHU, Rouen University Hospital, Rouen, France
    • Research Group MERCI (EA3829) and IHU, University of Medecin, Rouen, France
    • Corresponding Author InformationCorresponding author at: Pediatric Haematology and Oncology, Rouen University Hospital, 1, rue de Germont, 76000 Rouen, France. Tel.: +33 2 32 88 81 91; fax: +33 2 32 88 01 21.
    • ,
  • Odile Costa

      Affiliations

    • Research Group MERCI (EA3829) and IHU, University of Medecin, Rouen, France
    • ,
  • Elisabeth Legrand

      Affiliations

    • Research Group MERCI (EA3829) and IHU, University of Medecin, Rouen, France
    • ,
  • Dany Bigot

      Affiliations

    • Laboratory of Hemato-Biology, Rouen University Hospital, Rouen, France
    • ,
  • Sylviane Lecleire

      Affiliations

    • Laboratory of Hemato-Biology, Rouen University Hospital, Rouen, France
    • ,
  • Vanessa Grassi

      Affiliations

    • Department of Biostatistics, Rouen University Hospital, Rouen, France
    • ,
  • Jean-PierreVannier

      Affiliations

    • Pediatric Hematology, Oncology and IHU, Rouen University Hospital, Rouen, France
    • Research Group MERCI (EA3829) and IHU, University of Medecin, Rouen, France
    • ,
  • Marc Vasse

      Affiliations

    • Research Group MERCI (EA3829) and IHU, University of Medecin, Rouen, France
    • Laboratory of Hemato-Biology, Rouen University Hospital, Rouen, France

Received 26 January 2009 ,Revised 25 July 2009 ,Accepted 26 July 2009.

References 

  1. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696–1701
  2. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumour metastasis. Cancer Metastasis Rev. 2006;25:9–34
  3. Janowska-Wieczorek A, Marquez LA, Nabholz JM, Cabuhat ML, Montano J, Chang H, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood. 1999;10:3379–3390
  4. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004;50:87–100
  5. Chesler L, Golde DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood. 1995;86:4506–4515
  6. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitors of metalloproteinases-1. J Clin Invest. 1998;102:2002–2010
  7. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331–5338
  8. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245–2252
  9. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol. 1999;105:402–411
  10. Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res. 1999;19:4395–4400
  11. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res. 1999;5:1115–1124
  12. Kuittinen O, Savolainen ER, Koistinen P, Möttönen M, Turpeenniemi-Hujanen T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res. 2001;25:125–131
  13. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, Hara T. Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res. 2007;31:1437–1440
  14. Garand R, Béné MC. A new approach of acute lymphoblastic leukemia immunophenotypic classification: 1984–1994 the GEIL experience. Groupe d’Etude Immunologique des Leucémies. Leuk Lymphoma. 1994;13(Suppl. 1):329–342
  15. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24
  16. Schneider P, Vasse M, Corbiere C, Legrand E, Marie-Cardine A, Boquet C, et al. Endostatin variations in childhood acute lymphoblastic leukaemia—comparison with basic fibroblast growth factor and vascular endothelial growth factor. Leuk Res. 2007;31:629–638
  17. Donadieu J, Auclerc MF, Baruchel A, Perel Y, Bordigoni P, Landman-Parker J, et al. French Acute Lymphoblastic Leukaemia Group (FRALLE) Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE). Br J Cancer. 2000;12:1617–1622
  18. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;22(371):1030–1043
  19. Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). Cell Physiol. 2004;200:2–10
  20. Barillé S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997;90:1649–1655
  21. Swets JA, Pickett RM. Evaluation of diagnostic systems: methods for signal detection theory. New York: Academic Press; 1982;
  22. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol. 2002;117:835–841
  23. Pruijt JF, Fibbe WE, Laterveer L, Pieters RA, Lindley IJ, Paemen L. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci USA. 1999;96:10863–10868
  24. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122–3133
  25. Poyer F, Coquerel B, Pegahi R, Cazin L, Norris V, Vannier JP, et al. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk Res. 2009;33:407–417
  26. Schneider P, Vasse M, Legrand E, Callat MP, Vannier JP. Have urinary levels of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, a prognostic value in childhood acute lymphoblastic leukaemia?. Br J Haematol. 2003;122:163–164
  27. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood. 2006;107:1608–1616
  28. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992;298:29–32
  29. Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem. 1995;270:13453–13459
  30. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res. 1993;5:19–28

PII: S0145-2126(09)00386-5

doi: 10.1016/j.leukres.2009.07.039

Leukemia Research
Volume 34, Issue 1 , Pages 24-31 , January 2010

Article Tools

* Image Usage & Resolution